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Abstract: Glioblastoma (GB) has been shown to up-regulate autophagy with anti- or pro-oncogenic
effects. Recently, our group has shown how GB cells aberrantly up-regulate chaperone-mediated
autophagy (CMA) in pericytes of peritumoral areas to modulate their immune function through
cell-cell interaction and in the tumor’s own benefit. Thus, to understand GB progression, the
effect that GB cells could have on autophagy of immune cells that surround the tumor needs to
be deeply explored. In this review, we summarize all the latest evidence of several molecular
and cellular immunosuppressive mechanisms in the perivascular tumor microenvironment. This
immunosuppression has been reported to facilitate GB progression and may be differently modulated
by several types of autophagy as a critical point to be considered for therapeutic interventions.
Keywords: autophagy; chaperone-mediated autophagy; tumor; glioblastoma; perivascular cells;
pericytes; immunosuppressive; tumor immune tolerance; autophagy inhibitors
1. Introduction
Autophagy is essential to maintain cell homeostasis, acting as a protein/organelle quality control
mechanism in response to cellular or environmental stresses such as starvation, hypoxia, and
chemo/radiotherapy, which is required for cancer-cell survival and the adaptation to the disturbed tumor
microenvironment. Autophagy in cancer plays a dual role as a pro-tumorigenic or tumor-suppressive
mechanism, which depends on the stimulus and the cell type. The effects of autophagy change in
relation to the stage of tumor development and exhibit intratumoral heterogeneity, interfering with the
clinical application of autophagy activators or inhibitors. During the initiation of tumor development,
autophagy eliminates damaged organelles and aggregated proteins, and prevents DNA damage,
protecting cells from transformation into malignant cells and promoting tumor suppression via cellular
senescence [1–3]. However, once tumorigenesis is initiated, autophagy enhances establishment and
progression of the tumor [1,4–7].
Glioblastoma (GB), the most aggressive brain cancer, evades the immune system [8–11]. GB cells
interact with cells from perivascular areas and invade the brain parenchyma forming a functional
network of microtubes [12–15]. Several mechanisms have been described to favor GB progression. That
is the case of stablished interactions between GB cells and tumor surrounding cells, which are essential
to communicate and deliver organelles and nutrients, securing tumor survival [13,14,16]. Importantly,
the brain immune defense fails during GB progression, preventing anti-tumor immune responses that
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may be regulated by autophagy. Autophagy keeps the homeostasis of immune cells and modulates
the response to stressful stimuli. Autophagy regulates specific immune functions such as antigen
presentation, cell activation and differentiation [17–20]. Thus, as it occurs with anti-cancer direct
therapies, the use of autophagy modulators may affect the effectiveness of the current immunotherapies,
and could strengthen the immune system to eliminate the cancer cells [21–23].
In this review, we will focus on the current findings that identify different forms of autophagy in
GB cells and their functions in the tumor progression, with particular attention to perivascular brain
areas, where the tumor is established and progresses, escaping from the immune system. We will
describe how is the regulation and function of those autophagic pathways in immune cells, which
should contribute to the brain defense against GB, but instead, support tumor growth and fail to
promote anti-tumor immune responses.
Macroautophagy (also referred to as autophagy), microautophagy and chaperone-mediated
autophagy (CMA) are the main known types of autophagy. Those forms of autophagy differ in how
are regulated, the nature of the degraded substrates and in how the cargo is targeted to lysosomes.
However, there is little data on the functions of endosomal microautophagy in tumor cells [24,25] or in
the immune cells that could participate in the response to GB, macroautophagy and CMA are profusely
reported to have important roles in those cell types. In this manuscript, we will review these two types
of autophagy, focusing especially on CMA as an autophagy pathway that selectively degrades specific
proteins that modulate tumor progression in the immunosuppressive perivascular microenvironment,
which may constitute a promising target mechanism to treat this aggressive cancer.
2. Immune Suppressive Mechanisms in the Tumor Microenvironment
The immune system is highly specialized in the recognition of foreign antigens and unhealthy cells,
including tumor cells. However, cancers have developed different strategies to escape immune system
recognition and suppress the anti-tumor immune response. Specifically, it is well known that the brain
tumor microenvironment is characterized by secretion of a variety of anti-inflammatory molecules,
not only by tumor cells themselves, but also by other surrounding peritumoral cells previously
conditioned by the tumor. These peritumoral cells are peripheral immune cells (i.e., tumor-associated
macrophages (TAMs), T cells, myeloid-derived suppressor cells (MDSC) and T regulatory cells
(Tregs)), and various specialized organ-resident cells including microglial cells, astrocytes and
perivascular pericytes (PC) [8,10,13]. Collectively, anti-tumor innate and adaptive immune responses
in the tumor microenvironment are altered, and several mechanisms including decreased T cell
activation and proliferation, induction of anergic T cells, differentiation of Tregs, down-regulation
of major histocompatibility complex (MHC) expression and polarization of macrophages to an
immunosuppressive M2 phenotype, are prompted by tumor cells [22,26].
The great majority of immune cells infiltrating GB tumor mass are tissue-resident microglial cells
and bone marrow-derived macrophages (BMDMs) from circulating monocytes that migrate from
blood to brain parenchyma and differentiate to macrophages [22,27]. Together these cells have been
called TAM/Ms”. In GB, TAM/Ms displayed a pro-tumorigenic function, producing low amounts
of pro-inflammatory cytokines/growth factors and down-regulating expression of co-stimulatory
molecules such as CD40, CD80 and CD86 [27]. Moreover, glioblastoma and microglia interactions
favor GB progression by secretion of growth factors such as epidermal growth factor (EGF) and
colony stimulating factor-1 (CSF-1), or by up-regulation of CD163 and CD204 in infiltrating TAM/Ms,
mechanism that has been associated with a worse prognosis. TAM/Ms have been also described
to be involved in brain tumor angiogenesis and resistance to anti-angiogenic therapies [28], and to
stimulate glioma stem cell invasion through transforming growth factor β (TGFβ) signaling [29].
Other anti-inflammatory cytokine, IL-10, which is related to impaired T cell responsiveness in gliomas,
is selectively up-regulated in those tumors with invasive behavior compared to less malignant
counterparts [30].
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GB cells are also able to avoid anti-tumor T cell responses by several mechanisms, such as
prevention of antigen processing and presentation on MHC-class I, up-regulation of PD-L1 expression,
the ligand of the negative regulator receptor of T cell activation PD-1 (programmed cell death protein
1), or by increasing infiltration of Tregs and T cells with high expression of PD-1 and CTLA-4 (cytotoxic
T-lymphocyte-associated protein 4) [22,31,32].
PC have recently gained special attention due to their role in GB progression. PC are located on
the abluminal vessel wall, regulating vascular tone and morphology, and represent an immunological
defense in the brain modulating neuroinflammation [33–35]. However, PC also express PD-L1 and
acquire an immunosuppressive phenotype upon GB interaction, assisting GB to escape the immune
system recognition [13,36].
Many studies have provided compelling evidence that autophagy is involved in central
nervous system (CNS) tumor recurrence, and in chemotherapy and radiotherapy resistance [37],
suggesting that autophagy is other highly regulated mechanism that may contribute to tumor-induced
immune tolerance.
3. Autophagy in GB
3.1. Macroautophagy
Macroautophagy, also known as autophagy, is a process of lysosomal degradation and recycling
of cellular components by sequestering of cytosolic regions in de novo-generated double membrane
vesicles known as autophagosomes. Formed autophagosomes end up fusing with lysosomes to
degrade their contents. Macroautophagy can be either in bulk or selective. The selectivity is mediated
by autophagy receptors that bring cargo to the phagophore, including damaged organelles, intracellular
bacterial pathogens and aggregated proteins (Figure 1) [1,2,24,38–41].
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intracellular bacterial pathogens, and aggregated proteins. Macroautophagy sequesters cytosolic
contents in de novo-generated double membrane vesicles called autophagosomes that finally fuse
with lysosomes. Macroautophagy can be either in bulk or selective for a kind of cargo, and selectivity
is mediated by selective autophagy receptors (SAR), or Hsc70 chaperone for protein aggregates in
the case of Chaperone-Assisted Selective Autophagy (CASA). Selective macroautophagy binds cargo
to the phagophore through lipidated LC3 proteins anchored to the latter’s membrane. Endosomal
microautophagy, termed microautophagy in mammalian cells, caters on the degradation of cytosolic
regions by late endosomes recognizing the substrates to be degraded, both by bulk degradation of
proteins present in cytosol trapped in vesicles forming at the late endosome membrane, and by a
selective degradation after binding to Hsc70 chaperone though KFERQ-like motifs. Latter are sorted into
intraluminal vesicles in a manner dependent on the endosomal sorting complex required for transport
III (ESCRT-III). CMA is a selective process of degradation of soluble, amenable to unfolding, cytosolic
proteins presenting KFERQ-like motifs. The chaperone Hsc70 recognizes the motifs and transports
the protein substrates to the lysosome where they bind to LAMP2A. LAMP2A multimerizes being
stabilized by a glial fibrillary acidic protein (GFAP) and upon unfolding, the substrate is translocated
through the lysosomal membrane with the assistance of a lysosomal resident Hsc70, and degraded
in the lysosomal lumen. Both macroautophagy and CMA have anti- and pro-oncogenic roles, which
depend on the cellular context and are summarized here.
3.1.1. Regulation
Under normal conditions, basal level of autophagy is very low. Therefore, autophagy must be
induced through an efficient mechanism to survive stress and adapt extracellular signals. In mammalian
cells under nutrient-rich conditions, autophagy is inhibited by the serine/threonine-protein kinase
mTOR (mammalian target of rapamycin). mTOR negatively regulates other serine/threonine kinases,
Unc-51-like kinase-1 (ULK1) and -2 (ULK2), phosphorylating and inactivating Unc-51-like kinases
(ULKs) and autophagy-related gene 13 (Atg13) by binding to the ULKs-Atg13-FIP200 complex [42].
Under conditions of nutrient stress, AMP-dependent protein kinase (AMPK) increases autophagy
by inhibition of mTOR complex 1 (mTORC1), via phosphorylation of its Raptor subunit. Then, ULK1
and ULK2 are activated and phosphorylate Atg13 and FIP200. The beclin1 complex is recruited and
activates the class III PI3K VPS34, stimulating the autophagosome nucleation [42,43]. In addition,
other studies demonstrate that inhibition of mTORC1 promotes the transcription factors EB (TFEB) and
E3 (TFE3) nuclear translocation, inducing expression of autophagy–lysosome-relevant genes [44,45].
Autophagy is also induced by Exchange protein directly activated by cAMP 1 (Epac-1) through a
Ca2+/calmodulin-dependent kinase kinase b (CaMKKb)/AMPK signaling pathway [46]. Recently,
inositol polyphosphate multikinase (IPMK) has been reported to induce autophagy through the
regulation of AMPK/ULK activation and by enhancing autophagy-related transcription dependent of
Sirt-1 activation [47].
In tumor cells, there are many signaling pathways that participate in the regulation of autophagy.
Down-regulation of STAT/BCL2/BECLIN-1 [48–50] and PI3K/Akt/mTOR-mediated signaling pathways
can activate macroautophagy [51–53]. The Ras/Raf/ERK signaling pathway is one of the most
frequent pathways that activate macroautophagy in tumors [54,55]. Other important modulators of
macroauthophagy in GB are Sirt1 that induces autophagic cell death and mitophagy [56], insulin,
p53 [57], p38 mitogen-activated protein kinase (p38-MAPK) [58], 5′ AMPK [59], phosphatase and tensin
homolog deleted from chromosome 10 (PTEN) [60], and reactive oxygen species (ROS)-associated
pathways [61]. Furthermore, intracellular calcium signaling seems also an important regulatory
pathway in GB [62,63]. Recent advances in Hedgehog, NRF2-P62, and PD-L1/PD1 signaling pathways
seem to indicate that these might be potential targets to modulate macroautophagy in glioma [64–66].
It is important to highlight that in cancer cells, in general, acute amino acid starvation induces two
responses in parallel: mTOR inactivation with subsequent activation of in-bulk macroautophagy, and
induction of an immediate selective endosomal microautophagy independent of mTORC1 inactivation
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and canonical macroautophagy [24] (Figure 1). Both autophagic pathways likely work in concert and
may partially compensate for each other [67].
3.1.2. Functions
Most cells sustain low basal levels of macroautophagy that serve as a quality control system to
selectively degrade labeled damaged cargo [41,68–72]. However, autophagy plays a dual role in GB as
in other types of cancer, mediating oncogenic or oncosuppressive effects, acting as a “double-edged
sword” in tumors, depending on the cellular context and tumor type, the stage of tumor, cell viability
and intracellular environment [1–3,6].
In the early stages of oncogenic transformation, damaged proteins and organelles are efficiently
removed by macroautophagy, maintaining cell homeostasis, metabolism, and viability, which prevents
further tumor development [2,3]. Macroautophagy also prevents the accumulation of toxic molecules,
such as ROS produced by dysfunctional mitochondria, in addition to aggregates of ubiquitinated
proteins [73]. In addition to cytoprotective effects, autophagy exerts a death stimulation function
known as autophagy-dependent cell death, which is due to an excessive degradation of cell components
and organelles [3,74]. Moreover, several studies indicate that macroautophagy is activated in response
to several stressors, promoting glioma apoptosis [73,75,76].
Regarding the role of macroautophagy in epithelial-mesenchymal transition (EMT) of GB stem
cells, several studies implicate it in the promotion of EMT, while other works controversially suggest
that its inhibition may promote EMT and induce cancer-cell invasion [73,77,78].
During the advanced stages of tumors, macroautophagy is up-regulated, playing a crucial role in the
survival and development of GB, providing metabolic support and preventing senescence [6,7,79–81],
conferring resistance to chemotherapy, as well as supporting the maintenance, migration and invasion
of GSCs [73,82,83].
Therefore, treatment of tumors via macroautophagy regulation is extremely complicated because
it can be involved in cancer-cell survival or death. In addition, controversial results on macroautophagy
quantification in GB still exist in the literature. In fact, misinterpretations often occur when
assessing macroautophagy activity, which is often quantified by an increase in LC3 levels, which
does not necessarily reflect increased macroautophagy, since it may be due to an accumulation
of autophagosomes that do not fuse with lysosomes. Thus, the assessment of macroautophagy
status depends on a careful evaluation of several macroautophagy markers, such as LC3-I/II ratio,
subcellular localization, Atg12-Atg15 accumulation, and p62 degradation along with an assessment of
the macroautophagy flux [84].
3.2. Chaperone-Mediated Autophagy
CMA is a selective process of lysosomal degradation of soluble cytosolic proteins with KFERQ-like
motifs. The chaperone heat shock cognate 71 kDa protein (Hsc70) binds to the substrate protein by
recognition of the specific motifs and carry it to the lysosome with the help of another cochaperones.
The protein binds to the CMA receptor at the lysosomal membrane, the limiting component of this
pathway known as lysosome-associated membrane protein type 2A (LAMP2A). The protein is unfolded
and translocated into the lysosome to be degraded, also contributing other resident Hsc70 in the
lysosomal lumen (Figure 1) [85].
3.2.1. Regulation
Basal CMA levels are detectable in almost all types of mammalian cells, and its regulation is critical
to maintain cellular function and homeostasis. CMA failure leads, instead, to intracellular accumulation
of damaged proteins, defective regulation of many cellular functions, and failed responses to different
stressors [86–89]. CMA in tumor cells seems to be constitutively up-regulated [5]. Starvation, hypoxia,
and ROS, characteristics of the tumor microenvironment, activate CMA, but the mechanisms of
increased CMA activity in cancer cells are still poorly understood [87,89–94].
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Although there are no studies on how CMA is regulated in GB cells, it is interesting to consider
that mechanisms of CMA up-regulation in some cancer cells are the same as in non-transformed
cells [95,96]. In fact, during starvation, normal cells increase the levels of lysosomal LAMP2A by
reducing its lysosomal turnover [97], and in a same way, colorectal cancer cells up-regulate LAMP2A by
reducing their degradation through lowering levels of sorting nexin 10 (SNX10) [95]. Conversely, other
cancer cells use similar mechanisms as healthy cells, but with different results [98]. That is the case of
Hsp90 inhibition, which causes reduction of CMA activity by decreasing LAMP2A stabilization at the
lysosomal membrane in non-transformed cells, whereas in pancreatic cancer cells, Hsp90 inhibition
induces CMA activity and promotes IGF-1Rβ degradation [98]. In other cancer cells, pathways that
down-regulate CMA in normal cells, appear not to be functional. That is the case of several cancer-cell
lines that up-regulate CMA even in the presence of TORC2/AKT1 signaling pathway, which has a
CMA inhibitory effect in normal cells [99].
In most cell types, CMA blockade in vitro and in vivo causes the activation of macroautophagy and
the proteasome system [88,100]. Vice versa, the inhibition of macroautophagy or proteasome activates
CMA [101–104], which could be important for the maintenance of cell quality control and energy
balance at baseline conditions. However, although some cancer cells retain this autophagic crosstalk, in
most cancer cells, CMA is constitutively activated independently of the status of macroautophagy [5].
3.2.2. Functions
CMA is implicated in a wide variety of cellular functions such as protein quality control, response
to starvation, anti-ageing functions, transcriptional regulation, immune response, cell cycle and cancer
biology (Figure 1). CMA blockage in cancer cells has anti-cancer activity, decreasing cell proliferation
and tumorigenic/metastatic ability [4,5]. However, both reduced and increased CMA activity can
be pro-oncogenic depending on the cellular context, as reduced CMA increases DNA damage and
decreases proteostasis [94], providing an environment that facilitates malignant transformation [105].
However, once cells have undergone transformation, they up-regulate CMA to protect against oxidative
damage [4], degrade negative regulators of cell proliferation [106] and anti-oncogenes [107] and maintain
the metabolic switch favorable for cancer-cell growth [108,109]. Abnormally high levels of CMA are
shown in many cancer-cell lines and different types and stages of human tumors [4,5,110]. In fact,
genetic blockage of CMA in cancer-cell lines reduced their tumorigenic ability and CMA inhibition in
preformed xenografted tumors induced tumor shrinkage and lowered metastasis number [5].
Many cancer cells need CMA up-regulation to sustain aerobic glycolysis (Warburg effect), required
for cancer progression [5,109]. CMA plays an important role under hypoxia conditions in the
regulation of the tumor metabolism by degrading cell cycle regulatory proteins such as phosphorylated
serine/threonine-protein kinase (CHK1) [111] and hypoxia-inducible factor 1α (HIF1α) [112,113].
In addition, quantitative proteomics analysis of isolated lysosomes from CMA-activated conditions in
cancer cells has recently revealed a new role for CMA in the control of cell translation [114]. Importantly,
up-regulated CMA may also assist chemoresistance of GB, making them more resistant to different
stressors such as oxidative stress, hypoxia or even DNA damage agents [4,115]. Up-regulation of CMA
in GB cells that are in contact with perivascular areas, not only favors their proliferation, but it may
even interfere with the aberrant CMA up-regulation in tumor surrounding cells that benefits tumor
survival and affects anti-tumor immune microenvironment responses [36].
4. Autophagy in Immunosuppressive Cells during GB Progression
Immune cells can be modulated during tumor progression by autophagy activation or inhibition,
allowing them to promote anti-tumor immune responses or to fail in tumor clearance by inducing
tumor immune tolerance. Next, we describe autophagy in the different types of cells best known to
contribute in the immunosuppressive microenvironment of GB.
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4.1. Macroautophagy in Innate Immune Response
Macrophages and microglia are the main innate immune cells of the CNS which usually
facilitate tumor-mediated immunosuppression and tumor progression [22,27]. Infiltrated macrophage
populations contribute to up to 50% of non-neoplastic cells in the tumor microenvironment [27] and
require autophagy to maintain immune homeostasis. Macrophages use LC3-associated phagocytosis
(LAP), a type of non-canonical autophagy, to eliminate cells captured in phagosomes that fuse to the
lysosome, during tissue maintenance [18]. The failure of this pathway promotes impaired degradation
of phagocytosed cells, inducing systemic inflammatory disease that can help anti-tumor immunity [17]
(Figure 2). Induction of autophagy by activating c-Jun N-terminal kinase (JNK) and blocking
ATG5 cleavage is essential for differentiation of monocytes into macrophages, preventing monocyte
apoptosis and inducing cytokine production in response to granulocyte-macrophage colony-stimulating
factor (GM-CSF) [116]. Autophagy also plays an important role in MDSC polarization. The
inhibition of autophagy in macrophages (i.e., by knocking out Atg5 gene expression) promotes M1
polarization [117,118]. Furthermore, activation of autophagy in response to colony-stimulating factor-1
(CSF-1) and through AMPK signaling causes monocytes to differentiate into immunosuppressive
M2-like macrophages, contributing to tumor progression [17]. Blocking autophagy due to decreased
ATG16L1 expression enhances production of the pro-inflammatory cytokines IL-1β and IL-18,
suggesting that autophagy regulates inflammasome activation and controls production of those
cytokines [119] (Figure 2).
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Macroautophagy and CMA activation in different immune or brain-resident cells, represents a key point
of regulation to favors progression of tumor cells (green arrows) or to promotes its anti-tumor activity
(red arrows), respectively. Macroautophagy and CMA up-regulation support tumor progression by
increasing phagocytosis and by inhibiting inflammasome-mediated responses of TAMs and microglial
cells, and by stimulating differentiation of monocytes into anti-inflammatory M2 macrophages.
However, macroautophagy promotion hinders polarization of monocyte into pro-inflammatory M1
macrophages, which may represent an indirect mechanism to advantage tumor progression. Astrocytes
have direct physical contact with tumor cells whereas macroautophagy/CMA activity in this cell type
contributes to its anti-inflammatory phenotype. Neutrophils require macroautophagy to exert its
anti-tumor activity. Regarding the adaptive immune responses, T cells has been shown to require
macroautophagy and CMA to develop its anti-tumor activity by regulation of several immune
checkpoints (i.e., increasing cytokine release, proliferation, energy store mobilization, and degradation
of negative regulators of T cell activation or by prevention of T cell anergy). Macroautophagy
and CMA are also necessary for maintaining B cell-specific functions such as antigen presentation.
However, macroautophagy promotion favors tumor tolerance by stimulation of FoxP3 T regulatory cell
function. GB-induced CMA modulates pericytes immune function through cell-cell stable interactions
promoting GB survival and progression. GB-conditioned pericytes display an aberrant up-regulation
of CMA that lead to secretion of anti-inflammatory cytokines, angiogenic molecules, pro-regenerative
extracellular vesicles, and prevention of anti-tumor proteins secretion that benefits tumor growth.
Furthermore, GB-induced CMA in PC down-regulates expression of co-stimulatory molecules, prevents
pro-inflammatory cytokine secretion and fails to promote anti-tumor T cell responses, enhancing Treg
responses, which contributes to the immunosuppressive peritumoral niche of GB. Ig: immunoglobulins;
EVs: extracellular vesicles; EC: endothelial cells.
By contrast, neutrophils, other type of myeloid-derived cells that can develop an
immunosuppressive function in GB [120], require macroautophagy to induce inflammation [121,122].
Microglia, the tissue-resident macrophage population of the brain, also require autophagy to maintain
their ability to phagocytose apoptotic cells, protein aggregates and debris, and its failure enhances
inflammation as it occurs in macrophages [17]. Several publications show activation of primary mouse
microglia or microglial cell lines after knockdown of autophagy genes (i.e., Atg5 or Atg7) [123–125],
and characterize how the inflammatory response can be modulated by Beclin1-driven autophagy
through NLRP3 degradation [126] (Figure 2).
Reactive astrocytes establish direct cell interactions by gap junctions with tumor cells and microglial
cells at the peritumoral glial scar favoring tumor progression and chemoresistance. Astrocytes
contacting tumor cells secrete cytokines that support tumor metastasis in the brain and contribute to an
immunosuppressive microenvironment with high levels of anti-inflammatory cytokines such as IL-10,
TGFβ and CSF [10]. Autophagy/lysosomal dysfunction in astrocytes participates in neurodegeneration
as observed in lysosomal storage disorders [127]. However, little is known on the possible role of
macroautophagy in the immune function of astrocytes. Recent works show that this process is needed
for the homeostasis maintenance upon stimulation, but depending on the type of stressor, it can also
facilitate cell death and therefore brain inflammation [128–130] (Figure 2).
In summary, inhibition of macroautophagy in MDSC and glia lead to a pro-inflammatory response
that might alert the immune system to regress the tumor progression. However, it is important to
consider that macroautophagy inhibition can also impair phagocytosis and promote high toxicity and
inflammation, which can contribute to neurodegeneration associated with different diseases [125,126].
4.2. Macroautophagy in the Adaptive Immune Response
T cells, which can infiltrate the brain to promote tumor clearance, are found in peritumoral areas
during GB progression, being affected by several immune checkpoints that impair effective anti-tumor
responses. Macroautophagy role is essential in the maintenance of T cell homeostasis for the turnover
of organelles such as mitochondria. Macroautophagy prevents increased ROS accumulation that lead
to higher rates of cell death [131,132]. Macroautophagy inhibition deleting Atg gene or using chemical
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inhibitors negatively impacts the responses to antigen. Thus, it impairs activation-induced proliferation
upon T-cell receptor (TCR) engagement, which is associated with fast increased calcium levels [133].
Furthermore, recent works have shown selective degradation of inhibitors of cyclin-dependent kinases
or TCR signaling proteins, which contribute to T cell proliferation [132,134]. Importantly for tumor
progression, the accumulation of the protein tyrosine phosphatase PTPN1 in autophagy-deficient CD4+
T cells produces failed T cell responses upon priming and also after subsequent stimulation, which
seem to indicate that macroautophagy also regulates T cell tolerance [134]. Interestingly, IL-2 receptor
signaling enhances macroautophagy in peripheral CD4+ T cells by increasing LC3 expression, whereas
IFN-γ, T helper 1 cells signature cytokines, promotes macroautophagy in macrophages via the p38
MAPK signature pathway [135,136] (Figure 2).
Autophagy maintains the energy demands of the metabolism of CD4+ T cells, contributing to
sustain adenosine triphosphate (ATP) production in response to TCR engagement, proper anaerobic
glycolysis and mitochondrial respiration [133,134]. Autophagy-related (ATG) proteins-dependent
autophagic pathways also modulates T cell differentiation and function, regulating the generation of
different T cell populations [20]. Autophagy is also needed in FOXP3+ regulatory T cells (Treg) to
suppress anti-tumor immune responses, maintaining Treg cell homeostasis by prevention of metabolic
alterations that decrease their survival and may lead to autoimmunity [137]. Importantly, CD8+ T
cell memory generation and maintenance require of autophagy activity [138]. Recent works indicate
that the ability of autophagy to reprogram CD8+ T cell metabolism, contributes in modulation of the
efficacy of anti-tumor CD8+ T cell responses [139,140] (Figure 2).
Less has been reported about B cells in GB; however, it is important highlight that this type of
cell may possibly infiltrate GB during progression or regression after therapy, since they can act as
antigen-presenting cells (APCs) and may modulate tumor antigen-specific T cells [141,142]. IL-4, a
signature cytokine of T helper 2 cells can induce autophagy in B cells via a PI3K-dependent pathway,
promoting survival and antigen presentation of B cells [143]. Furthermore, macroautophagic activity
regulates B cell development, and its failure, leads to defective humoral immune response with
reduced secretion of immunoglobulins and failed activation upon the engagement of the B cell receptor
(BCR) [144,145] (Figure 2).
4.3. CMA in Innate Immune Response
Although little is known today about the role of CMA in the innate immune response, and
even less in the GB microenvironment, recent studies point to an increase in CMA in astrocytes
and microglia, as a protective mechanism against pathogenic crosstalk with neurons that causes
toxicity, inflammation and neurodegeneration [146,147]. A recent study in TAMs shows that LAMP2A
expression is up-regulated by tumor cells in several mouse tumor models and cancer patients’ samples.
Suppression of Lamp2a gene expression by either shRNA or CRISPR/Cas9 prevents TAMs activation and
tumor growth, whereas substrates degradation by CMA seems to promote macrophage pro-tumorigenic
activation [148] (Figure 2).
Recent studies of our group have revealed a new role of CMA in the immune function of
perivascular cells PC during GB progression and through interaction with tumor cells [13,36]. PC initiate
aberrant degradation of proteins in response to a burst of oxidative stress upon GB interaction, changing
the levels of secretion of several cytokines and of growth factor release, in a manner that supports
tumor cell proliferation and GB survival. GB induces CMA in PC to modulate stem-cell-like properties
and prevent secretion of anti-tumor proteins, facilitating tumor growth. Furthermore, GB-induced
CMA in PC enhances secretion of the anti-inflammatory cytokines TGFβ and IL-10 to promote an
immunosuppressive phenotype that leads to failed tumor antigen-specific T cell responses, facilitating
tumor tolerance. In a mouse model of xenografted GB cells, PC with impaired CMA, by knocking
out Lamp2a expression, promote antigen-specific T cell infiltration in the peritumoral areas, resulting
into tumor elimination. FOXP3+ Tregs populations hardly were infiltrated in those areas and reduced
expression of immune checkpoints, such as CTLA-4 and PD-1 in T cells, was detected [36]. This work
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supports that CMA inhibition in specific cells of the innate immune response of the brain, such as PC,
may be an effective approach to treat this aggressive disease (Figure 2).
4.4. CMA in the Adaptive Immune Response
So far, the role of CMA in CD8+ T cells in anti-tumor immunity is unknown. In CD4+ T cells, CMA
is essential for T cell activation, and its failure has been shown to impair T helper cell responses to
immunization and to infection by pathogens such as Listeria monocytogenes. CMA selectively degrades
two negative regulators of T-cell activation, the itchy homolog E3 ubiquitin protein ligase (ITCH) and
the regulator of calcineurin 1 (RCAN1), following stimulation of the TCR. High levels of those CMA
substrates are accumulated in CMA-deficient T cells and are responsible for decreased cytokine release
and T cell proliferation upon T cell activation [89] (Figure 2). Importantly, decreased or dysregulated
CMA with age in T cells, which also occurs in macroautophagy, may translate into altered quality
control, energy balance and proteome remodeling. Therefore, it would be also important to consider
the age to modulate autophagy in future therapies of GB that may affect T cells [20].
Finally, the important role of CMA in MHC-class II presentation of cytoplasmic antigens by B
cells [149,150] should be also considered during GB progression [141,142], since CMA in B cells might
facilitate anti-tumor T helper responses (Figure 2).
5. Are Drugs Targeting Autophagy an Effective Anti- GB Tumor Therapy?
Despite significant advances in conventional first-line therapeutic strategies for primary GB (i.e.,
surgical resection, radiotherapy and chemotherapy), tumor reappears in almost all patients, showing
a median survival of 12-15 months from initial diagnosis. Therefore, new therapeutic approaches
enhancing effectiveness of GB treatment are urgently needed.
As mentioned previously, macroautophagy and CMA are up-regulated in most
tumors [5,53,94,151,152], being the first even more increased after radiation and chemotherapy [37].
Autophagy has been considered to be a promising therapeutic mechanistic target to prevent progression
of a variety of tumors including GB [36,81]. Chloroquine and hydroxychloroquine are the only available
macroautophagy inhibitors in the clinical practice and they have already been used in several clinical
trials, alone or in combination with temozolomide (TMZ), showing a significant increased survival
in patients with GB [153,154]. Other reported macroautophagy inhibitors that sensitize GB cells
to chemotherapy are 3-methyladenine, wortmannin, bafilomycin A1 or siRNA for knocking down
expression of Rab7 or Atg7 genes [155–157]. However, it must be taken in consideration that autophagy
activation may also have deleterious effects on tumor cells, as a persistent stimulation of autophagy
may result in cell death. That is the case of rapamycin, LY294002, arsenic trioxide or tamoxifen [157].
Combination of drugs which increase autophagic flux such as tricyclic antidepressants (TCAs) and
certain anticoagulants (inhibitor of the purinergic receptor P2Y12) promotes autophagy-associated cell
death in glioma cells [158].
Considering that CMA regulatory mechanisms in some cancer cells act differently than in healthy
cells [94] (Figure 1), several CMA control points reported must be validated in each type of cancer:
(1) the first one is constituted by three proteins: mTOR2, Akt, and PHLPP1. While mTOR2 and Akt
inhibit CMA, dynamic recruitment of PHLPP1 to lysosomal membrane neutralizes this inhibitory
effect and activates CMA. This signaling axis may be blocked by using a selective inhibitor of
PHLPP1 [99]; (2) under conditions of oxidative stress, the transcription factor known as nuclear factor
of activated T-cells (NFAT) induces Lamp2 expression, an effect that is prevented by the calcineurin
inhibitor cyclosporine A or by blockade of ROS production by the anti-oxidant N-acetyl-cysteine [89];
(3) the transcription factor nuclear factor, erythroid derived 2, such as 2 (NFE2L2/NFR2) regulates
expression of Lamp2a, being the NFE2L2 deficiency associated with reduced LAMP2A levels [159];
(4) retinoic acid receptor alpha (RARα) has been found to negatively regulate LAMP2A expression,
and the RARα activator all-trans retinoic acid (ATRA) acts as a potent LAMP2A inhibitor [160];
(5) endoplasmic reticulum (ER) stress mediates p38MAPK activation which in turns phosphorylates
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LAMP2A and promotes CMA, a mechanism termed “ERICA” (ER stress-induced chaperone-mediated
autophagy) [161]; (6) Phosphopeptide P140, a fragment of the spliceosomal SNRNP70/U1-70K protein,
has been reported to alter the composition of HSPA8/HSC70 complexes and down-regulates LAMP2A
expression, thereby reducing CMA [162]; and (7) Unlike LAMP2A, the only LAMP2 isoform that
participates in CMA, LAMP2C negatively regulates melanoma growth and survival [163].
Antibiotics, such as cycloheximide, anisomycin and SB230580 seem to affect CMA activity whereas
geldanamycin acts as a CMA activator in some contexts [164], but selectively inhibits chaperone Hsp90
in others, inhibiting CMA in some types of tumor cells and showing anti-cancer activity [165,166].
However, as some of the cell components that control macroautophagy and CMA at different levels are
also involved in other signaling pathways that regulate key cellular processes other than autophagy,
pharmacological activation, or inhibition of any of these proteins could have significant non-specific
unwanted adverse effects.
Conversely, and although specific chemical inhibitors of CMA are not currently available in clinic,
expression levels and assembly of LAMP2A to the lysosomal membrane represent the only limiting
factor to regulate CMA activity [88]. In this regard, gene therapy directed to CMA only by blocking
LAMP2A expression could provide a much greater specificity to this type of anti-cancer strategies.
Thus, it has been found that blockade of LAMP2A expression delays growth and inhibits metastasis
of a variety of solid tumors [4,5,94,167]. In the case of GB, it has been recently addressed for the first
time that GB not only increase its CMA to survive and progress but GB cells also induce an abnormal
up-regulation of basal CMA in PC of brain peritumoral areas, to modulate PC immunosuppressive
phenotype through cell-to-cell interaction and facilitate GB progression [36]. Accordingly, inhibition of
CMA in PC (i.e., by knocking out LAMP2A expression) destabilizes GB-PC interactions and promotes
a secretory function on PC that contributes to removal of GB cells, a strategy that may be considered to
be a promising new therapy against GB.
In summary, the use of pharmacologic inhibitors or genetic therapy to inhibit macroautophagy
may prevent GB progression, but also promotes tumor immune tolerance. Therefore, future therapy in
brain peritumoral areas against Lamp2a expression could inhibit more specifically GB survival, through
impaired CMA, not only in the tumor cell but even in cells that interact with the tumor, preventing the
immunosuppressive microenvironment that facilitates tumor survival.
6. Conclusions and Future Perspectives
It must be considered that systemic administration of any autophagy inhibitor/activator will not
only affect tumor cells, but also all cell types present in the peritumoral microenvironment, a situation
that could lead to the occurrence of serious side effects. Moreover, the possible anti-tumor strategy to
be developed is further complicated considering that depending on the type of tumor cell or tumor
stage, macroautophagy could act as a pro- or anti-tumorigenic mechanism [3,73,81], a situation that
hinders the eligibility of an inhibitor or an activator of macroautophagy. CMA could represent a more
specific targetable mechanism to prevent GB progression, considering that current macroautophagy
inhibitors may have effects on many other cell processes different to macroautophagy, while targeting
Lamp2a gen may be specific for CMA.
Peritumoral areas, where GB progresses and where we can find tumor interactions with other
cells facilitating tumor growth, are promising targets to be considered for new treatments after tumor
surgery. As discussed above, genetic manipulations to block CMA in tumor cells or alternatively
in peritumoral cells could be a suitable therapeutic option to prevent tumor survival and avoid its
progression. However, CMA activity is also needed to maintain effector functions of T cells [89], which
are of key importance for complete tumor removal. Collectively, the ideal treatment for GB could
be constituted by a strategy that pursues the selective inhibition of CMA in the tumor and in the
peritumoral microenvironment, specifically in those cells in which CMA favors tumor progression such
as PC. Not less important would be to combine this treatment simultaneously with other therapeutic
strategies that boost tumor antigen-specific T cell responses, allowing the complete removal of the
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tumor. Combined immunotherapies able to cross blood-brain barrier or intrathecal therapy [23] (i.e.,
monoclonal antibodies, peptides, pro-inflammatory cytokines, dendritic cell vaccines, high dose IL-2
(HDIL-2) immunotherapy or chimeric antigen receptor T (CART) cell therapy against GB [168,169])
could lead to improved therapeutic results.
In conclusion, CMA could be considered to be a critical mechanism to be exploited as a promising
new gateway to enable an efficient anti-GB therapy.
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